Drug Profile
Rexlemestrocel L - Mesoblast/Teva Pharmaceutical Industries
Alternative Names: Allogeneic mesenchymal precursor cells - Mesoblast; Allogeneic STRO-3 immunoselected bone marrow-derived mesenchymal precursor cells (MPCs) - Mesoblast; CEP-41750; Mesenchymal stem cell therapy - Mesoblast; MPC 06; MPC-06-ID; MPC-150; MPC-150-IM; MPC-25; MPC-25-IC; MPC-25-Osteo; MPC-300; MPC-300-IV; MPC-75-IA; MPC-CBE; MPC-MICRO-IO; MSB-CAR001; NeoFuse; Replicart; Revascor; Rexlemestrocel-L - Mesoblast/Teva Pharmaceutical IndustriesLatest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Hanson Institute; Institute of Medical and Veterinary Science
- Developer Angioblast Systems; Boston Childrens Hospital; Mesoblast; Teva Pharmaceutical Industries
- Class Anti-inflammatories; Anti-ischaemics; Antihypercalcaemics; Antineoplastics; Antirheumatics; Heart failure therapies; Mesenchymal stem cell therapies; Skin disorder therapies; Stem cell therapies; Vascular disorder therapies
- Mechanism of Action Cell replacements; Osteogenesis stimulants; Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Acute myeloid leukaemia; Back pain; Heart failure; Hodgkin's disease; Intervertebral disc degeneration; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Phase II Myocardial infarction; Osteoarthritis; Rheumatoid arthritis; Spondylosis; Type 2 diabetes mellitus
- Phase I/II Diabetic nephropathies; Hypoplastic left heart syndrome
- No development reported Age-related macular degeneration; Fracture; Lung disorders; Peripheral arterial disorders; Skin ulcer
Most Recent Events
- 22 Mar 2024 Mesoblast plans a phase III trial for Back pain and Intervertebral disc degeneration (Intralumbar, Injection) (NCT06325566)
- 11 Mar 2024 Mesoblast announces intention to request a pre-BLA meeting with FDA to discuss data presentation, timing and FDA expectations for an accelerated approval filing in end-stage ischemic HFrEF patients with LVAD implantation
- 11 Mar 2024 Mesoblast announces intention to submit NDA to USFDA for Heart failure